Pharmacokinetics of Two Novel Formulations of Modified-Release Oral Testosterone Alone and With Finasteride in Normal Men With Experimental Hypogonadism

    November 2010 in “ International Journal of Andrology
    C. N. Snyder, Richard F. Clark, Ralph B. Caricofe, Mark B. Bush, Mara Y. Roth, Stephanie T. Page, William J. Bremner, John K. Amory
    Image of study
    TLDR New oral testosterone formulations show potential for safer, effective hormone replacement in men with low testosterone.
    This study investigated the pharmacokinetics of two novel formulations of modified-release oral testosterone, alone and with finasteride, in normal men with experimental hypogonadism. The modified slow-release formulation appears to prevent the transient postdose supraphysiologic peaks in serum hormone levels observed with the other formulations by slowing hormone absorption. This formulation appears to be attractive for further development as an oral form of testosterone and will be the focus of future studies investigating the safety and efficacy of this approach to androgen replacement therapy in hypogonadal men.
    Discuss this study in the Community →

    Cited in this study

    3 / 3 results

    Related

    2 / 2 results